Pan-cancer Companies: Competitive Analysis
Pathway Genomics, Guardant Health, Exosome Diagnostics, Biocept, and Trovagene are five companies similar to GRAIL for which we conducted a competitive analysis. Each company is working in pan-cancer analysis, or screening for multiple or all groups of cancer at the same time, through means other than DNA sequencing. We have compiled all the information regarding each company, including an overview, their screening method, location, funding and sources, in the attached spreadsheet.
We were able to identify the competitors of GRAIL from this article which talked about companies that are currently conducting pancreatic cancer research based on liquid sequencing. GRAIL aims to "develop a blood test to detect cancer early before symptoms appear" by performing liquid biopsy screening and sequencing. Therefore, we focused on companies that did the same, and are trying to understand and detect cancer before the symptoms start showing in patients.
The first competitor to GRAIL is Pathway Genomics which is currently developing the CancerIntercept Monitor. The monitor can so far do tumor profiling, monitoring of treatment efficacy, monitoring of disease progression and tumor evolution, and monitoring of residual disease. CancerIntercept works as a liquid biopsy method.
Guardant Health is most known in the medical community for unveiling clinical trial results which showed that the company's "liquid biopsy platform detected disease-associated genetic mutations that were also present in 94% to 100% of the solid tissues extracted from the study’s subjects", therefore effectively screening for cancer via liquid biopsy. While not directly relevant to this research, it is important to note that the company is currently also trying to sequence the tumor DNA of more than 1 million cancer patients in the next five years.
Exosome Diagnostics developed a method where they use exosomes and other microvesicles which are then "shed into biofluids, which include blood, urine and cerebrospinal fluid". This forms "a highly enriched source of intact, disease-specific nucleic acids". Exosome Diagnostics developed proprietary exosome technology which "makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases".
Biocept specializes in cell separation technology. Their Cell Enrichment and Extraction platform "combines sophisticated attachment chemistry with mathematically modeled fluid dynamics to enable earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within their state-of-the-art CLIA-accredited laboratory".
Trovagene is currently developing liquid biopsy tests which "provide actionable information about EGFR mutations, often associated with common solid tumor cancers". The special thing about Trovagene is that their liquid biopsy tests "detect driver and resistance mutations as low as 0.006% sensitivity" which is "10 times greater than other liquid biopsy methods available today".
We have compiled all the information regarding each company, including an overview, their screening method, location, funding and sources, in the attached spreadsheet.
Pathway Genomics, Guardant Health, Exosome Diagnostics, Biocept, and Trovagene are five companies similar to GRAIL for which we conducted a competitive analysis. We have compiled all the information regarding each company in the attached spreadsheet.